abstract |
The present invention relates to oral suspension dosage form of Edaravone. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form. Moreover, the solubility and stability of the patient compliant Edaravone formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides a suspension composition prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible. |